ArticleJournal of molecular histology2025
S1PR5 as a prognostic biomarker in colon cancer: insights into efferocytosis-related mechanisms and immune modulation.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Decoding the S1P-S1PR axis in cancer: Mechanisms, pathways and therapeutic horizons (Review).Biomedical reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colon cancer remains a major cause of global cancer mortality, characterized by complex interactions between genetic, epigenetic, and immune factors. This study investigates the prognostic value of efferocytosis-related genes and their role in colon cancer progression and immune modulation. A prognostic signature relied on efferocytosis-related genes was developed using univariate Cox and least absolute shrinkage and selection operator (LASSO) regression analyses. Immune infiltration, immune checkpoint expression, and tumor microenvironment characteristics were analyzed using single-sample gene set enrichment analysis (ssGSEA), ESTIMATE, and tumor immunophenotype (TIP) frameworks. S1PR5 was knocked down in SW1116 and SW620 cells. The effect of S1PR5 on colon cancer growth and macrophage regulation in vivo and in vitro. Colon cancer patients were stratified into high- and low-risk groups, with high-risk patients demonstrating significantly worse survival outcomes. S1PR5, a key gene in the model, was markedly overexpressed in colon cancer tumors and correlated with advanced clinical stages, poor survival outcomes, and diminished responses to immunotherapy. Furthermore, S1PR5 knockdown could inhibit colon cancer cell activity and increase macrophage polarization from M0 to M1. Our research developed an efferocytosis-related gene prognostic model and identified S1PR5 as a key biomarker. S1PR5 showed significant associations with advanced clinical stages, immunosuppressive microenvironments, and unfavorable survival outcomes, underscoring its potential as both a prognostic marker and a therapeutic target in colon cancer.
Indexed as
Identifiers
40952538What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.